Formycon Ag · XETR:FYB
Formycon — 9M 2023 Earnings Presentation
17 slides from Formycon's earnings presentation, Nov 13, 2023
Slide 1: Formycon AG Earnings Call 9M 2023
November 13, 2023 15:00 (CET) Formycon AG Earnings Call 9M 2023
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Welcome to our Q3 call! Formycon Management Team
Welcome to our Q3 call! Formycon Management Team Dr. Stefan Glombitza, Nicola Mikulcik Dr. Andreas Seidl, Enno Spillner, CEO of Formycon CBO of Formycon CSO of Formycon CFO of Formycon ● More than 20 years of ● 12 years Global Head of ● More than 20 years of ● More than 24 years of experience in pha
Slide 4: Contributing to ease the financial strains on the world's healthcare systems
Vision & Mission Pioneering Work in Biosimilar Development Contributing to ease the financial strains on the world’s healthcare systems Formycon AG The Biosimilar Experts 4 Formycon AG — 9M 2023
Slide 5: Improving Patient Access to Vital Medicines
Vision & Mission Pioneering Work in Biosimilar Development Improving Patient Access to Vital Medicines Formycon AG The Biosimilar Experts 5 Formycon AG — 9M 2023
Slide 6: Strong and broad Biosimilar-Pipeline
Strong and broad Biosimilar-Pipeline Diversified portfolio of commercial, late and mid stage programs Multiple catalysts over the next 12 – 18 months Lucentis® Approvals Ophthalmology 50% owned CA, AUS, +++ Expired $2.9bn (Genentech Inc.) US: 06/2020, EU: 07/2022 2022 [US] [ex-US] [MENA] Stelara® Su
Slide 7: Highlights 2023 – Late-stage Programs reached multiple important milestones
Highlights 2023 – Late-stage Programs reached multiple important milestones Lucentis® Biosimilar Stelara® Biosimilar Candidate Eylea® Biosimilar Candidate [Ranibizumab] [Ustekinumab] [Aflibercept] ● FYB201 is out-performing biosimilar ● Global out-licensing deal signed ● Successful completion of Pha
Slide 8: Highlights 2023 – 2nd wave of Projects showing good progress
Highlights 2023 – 2nd wave of Projects showing good progress Keytruda® Biosimilar Candidate Undisclosed [Pembrolizumab] Biosimilar Candidates ● FYB206 is in an advanced ● Undisclosed immunology preclinical development stage and Biosimilar candidates FYB208 and is expected to enter clinical trials FY
Slide 9: Financial Position – Performance 9M/2023
Financial Position PERFORMANCE 9M/2023 9 Formycon AG — 9M 2023
Slide 10: Statement of comprehensive Income reflects successful Transformation
Statement of comprehensive Income reflects successful Transformation 9M 2023 vs. 9M 2022 In € K 9M 2023 9M 2022 Change in % Remarks • Record revenues at Formycon • Revenue consist of success payments (Fresenius), Revenue 60,222 28,231 +113.3 % FYB201 licensing revenues (2,2m€) and services for FYB20
Slide 11: Statement of financial Position – further stabilising
Statement of financial Position – further stabilising 9M 2023 vs. Dec. 31, 2022 In € K 9M 2023 Dec. 31, 2022 Change in % Remarks • Capitalisation FYB206 Non-current assets 799,349 823,195 -3.0% • Adjustment Bioeq AG • +68m net capital increase • +25m FYB202 success payments Cash and cash equivalents
Slide 12: Group asset Structure as of September 30, 2023
Group asset Structure as of September 30, 2023 Total equity and liabilities Equity Liabilities € 877,784K € 500,539K € 377,245K + € 24,087K + € 143,959K - € 119,872K + 3% +40% -24% Equity Ratio Non-current assets vs. Cash & Cash Equivalents Total equity and liabilities 57.0% € 35,631K +15% 91% + € 2
Slide 13: Guidance 2023 fully on track
Guidance 2023 fully on track Guidance Update for Fiscal year Revenue EBITDA Working Capital Net income Net income • Guidance: 2023 + Topline and EBITA guidance current forecast 75 to 85 -15 to -5 15 to 25 -20 to -30 vs. 50 to 60 unchanged + Significant Increase in net income € million € million € mi
Slide 14: Formycon on the Stock Market
Formycon on the Stock Market ● Listed on Frankfurt Stock Exchange since June 2012 / Shareholder Structure SME segment “Scale” (Open Market) ● ~54 % Anchor Investors incl. Athos KG, Active ● Registered capital: € 16,038,775 Ownership Capital, Wendeln & Cie. KG, DSP Shares outstanding: 16,038,775 (w/o
Slide 15: Outlook – operational, regulatory and commercial news flow to be expected
Outlook – operational, regulatory and commercial news flow to be expected … Lucentis® Biosimilar Stelara® Biosimilar Candidate Eylea® Biosimilar Candidate [Ranibizumab] [Ustekinumab] [Aflibercept] ● Product launches in further ● Regulatory submissions in the ● EU-regulatory submission attractive mar
Slide 16: Key Investment Highlights
Key Investment Highlights Commercial-stage Potential to address a large and Proof of capabilities with recent biosimilar-focused biotechnology growing market with constantly Lucentis® biosimilar approvals and company expanding product pipeline successful launches Remarkable pipeline including Effici
Slide 17: We are happy to answer your questions
Formycon AG WE ARE HAPPY TO ANSWER YO U R Q U E S T I O N S www.formycon.com 17 Formycon AG — 9M 2023